Caligan Partners Lp
Institutional manager — quarterly 13F holdings, Q ending 2026-03-31
Reported value
$1.50B
Q ending 2026-03-31
Prior quarter
$1.21B
Q ending 2025-12-31
Change
+23.7% QoQ · +213.6% YoY
Positions
28
reported holdings
Largest positions
All 28 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
| Holding | Ticker | Type | Value ▼ | Shares |
|---|---|---|---|---|
| Liquidia Corporation | LQDA | Shares | $306.4M | 8.1M |
| Abivax Sa | ABVX | Shares | $162.8M | 1.5M |
| Revolution Medicines Inc | RVMD | Shares | $160.7M | 1.7M |
| Vaxcyte Inc | PCVX | Shares | $119.7M | 2.1M |
| Xenon Pharmaceuticals Inc | XENE | Shares | $81.0M | 1.4M |
| Mineralys Therapeutics Inc | MLYS | Shares | $75.1M | 2.8M |
| Exelixis Inc | EXEL | Shares | $66.6M | 1.6M |
| Cg Oncology Inc | CGON | Call | $60.9M | 900K |
| Tango Therapeutics Inc | TNGX | Shares | $50.4M | 2.4M |
| Tyra Biosciences Inc | TYRA | Shares | $48.9M | 1.3M |
| Spyre Therapeutics Inc | SYRE | Shares | $44.3M | 878K |
| Adma Biologics Inc | ADMA | Shares | $42.9M | 4.8M |
| Lb Pharmaceuticals Inc | LBRX | Shares | $34.6M | 1.4M |
| Vor Biopharma Inc | VOR | Shares | $34.3M | 1.9M |
| Sab Biotherapeutics Inc | SABS | Shares | $30.5M | 8.0M |
| Opus Genetics Inc | IRD | Shares | $27.6M | 6.1M |
| Inventiva Sa | IVA | Shares | $27.6M | 5.0M |
| Mbx Biosciences Inc | MBX | Shares | $25.3M | 849K |
| Avalo Therapeutics Inc | AVTX | Shares | $24.4M | 1.6M |
| Revolution Medicines Inc | RVMD | Call | $22.3M | 229K |
| Anika Therapeutics Inc | ANIK | Shares | $20.8M | 1.4M |
| Maze Therapeutics Inc | MAZE | Shares | $18.4M | 615K |
| Verrica Pharmaceuticals Inc | VRCA | Shares | $4.9M | 924K |
| Sensei Biotherapeutics Inc | FTH | Shares | $4.0M | 126K |
| Agios Pharmaceuticals Inc | AGIO | Call | $3.0M | 90K |
| Adma Biologics Inc | ADMA | Call | $2.7M | 300K |
| Aura Biosciences Inc | AURA | Shares | $1.5M | 230K |
| Xilio Therapeutics Inc | XLO | Shares | $943K | 112K |
Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.